Core Insights - The conference highlighted the importance of early prevention and standardized treatment for severe asthma to prevent progression to chronic obstructive pulmonary disease (COPD) and achieve "clinical cure" [1][2] Group 1: Disease Prevalence and Impact - Chronic respiratory diseases, including severe asthma and COPD, pose significant health threats in China, with over 45.7 million asthma patients aged 20 and above, of which 5%-10% are classified as severe asthma [1] - Nearly 100 million individuals suffer from COPD, making it the third leading cause of death in the country [1] Group 2: Treatment Challenges and Innovations - Many asthma patients remain undiagnosed or receive inadequate treatment, often misunderstanding that medication alone suffices, while inhaled corticosteroids and bronchodilators are crucial for effective management [2] - The introduction of biologics has provided new hope for the treatment of severe asthma, aiming for "clinical cure" and enhancing management strategies for respiratory diseases [2] Group 3: Healthcare System Initiatives - The Chinese government is advancing initiatives for early screening, diagnosis, and treatment of chronic respiratory diseases, improving the service system for managing asthma and COPD [2]